Fresenius Kabi Patent-Cliff Exposure & CMS Drug Spending Portfolio

Fresenius Kabi (Lake Zurich, IL): 68 reconciled FDA prescription therapies, $1.29B 2024 CMS Part D & Medicaid spend, and 143 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterLake Zurich, IL
Reconciled FDA Portfolio Therapies68
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2026-01-01
2024 CMS Total Public Spend$1.29B
2024 Medicare Part D Spend$506.0M
2024 Medicaid Spend$783.5M
California HCAI SB 17 Filings143 WAC filings (max 362.0% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Fresenius / Fresenius Kabi across sibling Meru public-data platforms.